Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

Dimensional Fund Advisors LP grew its position in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 270.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 264,069 shares of the company's stock after purchasing an additional 192,714 shares during the period. Dimensional Fund Advisors LP owned about 0.66% of Solid Biosciences worth $1,056,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Renaissance Technologies LLC grew its position in Solid Biosciences by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 82,493 shares of the company's stock worth $330,000 after acquiring an additional 9,281 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Solid Biosciences during the fourth quarter worth $49,000. Wells Fargo & Company MN grew its holdings in shares of Solid Biosciences by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock worth $53,000 after purchasing an additional 2,986 shares during the last quarter. Trexquant Investment LP increased its stake in shares of Solid Biosciences by 256.9% in the fourth quarter. Trexquant Investment LP now owns 194,281 shares of the company's stock valued at $777,000 after buying an additional 139,851 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Solid Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 509,802 shares of the company's stock valued at $2,040,000 after buying an additional 4,932 shares during the last quarter. Institutional investors own 81.46% of the company's stock.

Analysts Set New Price Targets

SLDB has been the topic of a number of research reports. HC Wainwright upped their target price on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Piper Sandler lowered their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Barclays cut their price target on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Finally, Chardan Capital lowered their price objective on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Monday. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $14.78.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $2.70 on Thursday. Solid Biosciences Inc. has a fifty-two week low of $2.41 and a fifty-two week high of $10.37. The stock has a market capitalization of $209.26 million, a PE ratio of -0.89 and a beta of 2.32. The business's 50-day simple moving average is $3.37 and its 200-day simple moving average is $4.16.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). On average, research analysts expect that Solid Biosciences Inc. will post -2.84 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.